Treasury weighs adding biotech to outbound investment screening rules, a move that could chill or block US deals with China biotechs.
Officials at the Treasury Department are looking at potential restrictions on US investments in China biotech, according to multiple sources familiar with the discussions.
At …
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
US lawmakers push Treasury to screen outbound biotech investments in China under the COINS Act. BINSA bill targets pharmaceutical…
As large biopharma companies have increasingly turned to China for novel biotech innovation, political calls in the U.S. to block…
A key US House Republican urges Treasury to restrict US investment in China biotech, spotlighting Bristol Myers Squibb's Hengrui…
BIO makes China political strategy a top priority as US weighs outbound investment limits; CEO Crowley says biotech may fall…
China’s biotech boom continues to attract Western drug makers even as Washington expands investment and technology controls.
Two federal lawmakers have introduced a bill seeking to apply the review requi | Two federal lawmakers have introduced a bill…
